A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Review: Infliximab for rheumatoid arthritis 2006<br />
Comparison: 03 Infliximab i.v. licensed dose only (3 mg kg –1 every 8 weeks) + MTX vs Placebo + MTX, end <strong>of</strong> trial<br />
Outcome: 07 SAEs<br />
Study<br />
or subcategory<br />
Infliximab<br />
n/N<br />
Placebo<br />
n/N<br />
01 With concurrent, ongoing MTX<br />
START, 111 [22 weeks] (+)<br />
ATTRACT, 132,133 [54 weeks] (+)<br />
Subtotal (95% CI)<br />
Total events: 38 (infliximab), 45 (placebo)<br />
Test for heterogeneity: 2 = 2.11, df = 1 (p = 0.15), I2 28/360 27/361<br />
10/88 18/86<br />
448 447<br />
= 52.7%<br />
Test for overall effect: z = 0.84 (p = 0.40)<br />
02 With concurrent, newly initiated MTX (infliximab + MTX vs MTX)<br />
ASPIRE, 135 [54 weeks] (+)<br />
Subtotal (95% CI)<br />
Total events: 52 (infliximab), 32 (placebo)<br />
Test for heterogeneity: NA<br />
Test for overall effect: z = 1.14 (p = 0.25)<br />
52/372 32/291<br />
372 291<br />
Total (95% CI)<br />
Total events: 90 (infliximab), 77 (placebo)<br />
Test for heterogeneity: 2 = 4.09, df = 2 (p = 0.13), I2 820 738<br />
= 51.1%<br />
Test for overall effect: z = 0.21 (p = 0.84)<br />
FIGURE 42 SAE RR: infliximab licensed dose versus placebo (with concurrent MTX)<br />
© Queen’s Printer and Controller <strong>of</strong> HMSO 2006. All rights reserved.<br />
Health Technology Assessment 2006; Vol. 10: No. 42<br />
RR (fixed)<br />
95% CI<br />
0.1 0.2 0.5 1 2 5 10<br />
Favours infliximab Favours placebo<br />
Review: Infliximab for rheumatoid arthritis 2006<br />
Comparison: 03 Infliximab i.v. licensed dose only (3 mg kg –1 every 8 weeks) + MTX vs Placebo + MTX, end <strong>of</strong> trial<br />
Outcome: 07 SAEs<br />
Study<br />
or subcategory<br />
Infliximab<br />
n/N<br />
Placebo<br />
n/N<br />
01 With concurrent, ongoing MTX<br />
START, 111 [22 weeks] (+)<br />
ATTRACT, 132,133 [54 weeks] (+)<br />
Subtotal (95% CI)<br />
Total events: 38 (infliximab), 45 (placebo)<br />
Test for heterogeneity: 2 = 3.00, df = 1 (p = 0.08), I2 28/360 27/361<br />
10/88 18/86<br />
448 447<br />
= 66.7%<br />
Test for overall effect: z = 0.84 (p = 0.40)<br />
02 With concurrent, newly initiated MTX (infliximab + MTX vs MTX)<br />
ASPIRE, 135 [54 weeks] (+)<br />
Subtotal (95% CI)<br />
Total events: 52 (infliximab), 32 (placebo)<br />
Test for heterogeneity: NA<br />
Test for overall effect: z = 1.16 (p = 0.25)<br />
52/372 32/291<br />
372 291<br />
Total (95% CI)<br />
Total events: 90 (infliximab), 77 (placebo)<br />
Test for heterogeneity: 2 = 4.26, df = 2 (p = 0.12), I2 820 738<br />
= 53.0%<br />
Test for overall effect: z = 0.21 (p = 0.84)<br />
FIGURE 43 SAE RD: infliximab licensed dose versus placebo (with concurrent MTX)<br />
RD (fixed)<br />
95% CI<br />
–1 –0.5 0 0.5 1<br />
Favours infliximab Favours placebo<br />
Weight<br />
%<br />
33.25<br />
22.46<br />
55.71<br />
44.29<br />
44.29<br />
100.00<br />
Weight<br />
%<br />
46.57<br />
11.24<br />
57.81<br />
42.19<br />
42.19<br />
100.00<br />
RR (fixed)<br />
95% CI<br />
1.04 (0.63 to 1.73)<br />
0.54 (0.27 to 1.11)<br />
0.84 (0.56 to 1.26)<br />
1.27 (0.84 to 1.92)<br />
1.27 (0.84 to 1.92)<br />
1.03 (0.77 to 1.38)<br />
RD (fixed)<br />
95% CI<br />
0.00 (–0.04 to 0.04)<br />
–0.10 (–0.20 to 0.01)<br />
–0.02 (–0.05 to 0.02)<br />
0.03 (–0.02 to 0.08)<br />
0.03 (–0.02 to 0.08)<br />
0.00 (–0.03 to 0.03)<br />
67